AGEN digging through the Crates
AGEN hasn't done this in years...what? It hasn't sustained these levels for any meaningful amount of time. I did a quick fib retracement using those 2017 highs as the upper anchor and you can see what has revealed itself. The 236 area is a key pivot. Most of the time it has acted as a resistance pivot. But, so far AGEN has held these levels. Where does it go from here? A lot of that might have to do with what's coming."pipeline treatments like AGEN1777 have gained interest from some of the industry’s leading names. Bristol Myers Squibb (
BMY) has a global exclusive license with Agenus providing up to $200 million in cash upfront. The company can also receive up to $1.36 billion if it reaches specific milestones and includes royalties upon any sales. The FDA already cleared an Investigational New Drug Application for a Phase 1 dosing with AGEN1777 alone and combined with an anti-PD-1 in solid tumors. That’s expected to begin this quarter...Balstilimab...is something that could be in focus as well. The FDA accepted a Biologics License Application for priority review. A Prescription Drug User Fee Act (PDUFA) target date was also given. December 16th will be the PDUFA date and could present an important one for the company and Balstilimab. Phase 2 data showed a response rate of 20% in PD-L1 positive tumors, an overall response rate of 15%, and a median duration of response of 15.4 months. Furthermore, Phase 2 trial results of balstilimab combined with zalifrelimab (AGEN1884) will be presented at a Mini Oral Session at the European Society for Medical Oncology Congress next month. So plenty to watch if AGEN stock is on your watch list right now."Quote Source & Read more On AGEN: Hot Biotech Stocks That Deserve Your Attention In August 2021
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.